. Association between the expression levels of 5-FU metabolism-related enzymes and clinical outcomes, excluding patients who received adjuvant 5-FU chemotherapy. Among the patients who did not receive adjuvant 5-FU chemotherapy, the overall survival rates (shown by Kaplan-Meier curves) for those with higher expression levels of (A) DPD, (B) OPRT and (C) TS in their primary tumors were compared with those showing lower expression. The progression-free survival rates (shown by Kaplan-Meier curves) for the patients with higher expression levels of (D) DPD, (E) OPRT and (F) TS were also compared. The patients with higher expression levels of TS and the patients with lower expression levels of DPD exhibited lower progressionfree survival rates (P<0.05 determined by log rank test). NS, not significant; 5-FU, 5-fluorouracil; DPD, dihydropyrimidine dehydrogenase; OPRT, orotatephosphoribosyltransferase; TS, thymidylate synthase. Figure S2 . Association between the efficacy of adjuvant 5-FU chemotherapy and the expression of OPRT. (A) The overall survival rates (shown by Kaplan-Meier curves) of patients with lower expression levels of OPRT who received adjuvant 5-FU chemotherapy were compared with those of patients who did not. The UC-UUT patients who received 5-FU all had LVI, and among those who did not receive 5-FU, some had LVI and some did not. No significant differences were observed. (B) The overall survival rates (shown by Kaplan-Meier curves) of patients with higher expression levels of OPRT who received adjuvant 5-FU chemotherapy were compared with those of patients who did not. The UC-UUT patients who received 5-FU all had LVI, and among those who did not receive 5-FU, some had LVI and some did not. No significant differences were observed. (C) The overall survival rates (shown by Kaplan-Meier curves) of patients with lower expression levels of OPRT who received adjuvant 5-FU chemotherapy were compared with those of patients with higher expression levels of OPRT who also received the therapy. The two groups were comprised of UC-UUT patients with LVI. No significant differences were observed. (D-F) Progressionfree survival rates were also investigated with the same 3 group comparisons, and no significant differences were observed. NS, not significant; LVI, lymphovascular invasion; 5-FU, 5-fluorouracil; UC-UUT, urothelial carcinoma of the upper urinary tract; OPRT, orotatephosphoribosyltransferase. Figure S3 . Association between the efficacy of adjuvant 5-FU chemotherapy and the expression of TS. (A) The overall survival rates (shown by Kaplan-Meier curves) of patients with lower expression levels of TS who received adjuvant 5-FU chemotherapy were compared with those of patients who did not. The UC-UUT patients who received 5-FU all had LVI, and among those who did not receive 5-FU, some had LVI and some did not. No significant differences were observed. (B) The overall survival rates (shown by Kaplan-Meier curves) of patients with higher expression levels of TS who received adjuvant 5-FU chemotherapy were compared with those of patients who did not. The UC-UUT patients who received 5-FU all had LVI, and among those who did not receive 5-FU, some had LVI and some did not. No significant differences were observed. (C) The overall survival rates (shown by Kaplan-Meier curves) of patients with lower expression levels of TS who received adjuvant 5-FU chemotherapy were compared with those of patients with higher expression of TS who also received the therapy. The two groups were comprised of UC-UUT patients with LVI. No significant differences were observed. (D-F) Progression-free survival rates were also investigated with the same 3 group comparisons, and no significant differences were observed. NS, not significant; LVI, lymphovascular invasion; 5-FU, 5-fluorouracil; UC-UUT, urothelial carcinoma of the upper urinary tract; TS, thymidylate synthase.
